The success of GLP-1 therapies in treating diabetes and obesity proves peptides are powerful therapeutic agents capable of addressing large unmet needs, and innovative new peptide therapies are now in development for psoriasis and other I&I conditions. Orals could grow the markets substantially.
Novo Nordisk’s Ozempic and Wegovy, along with Eli Lilly’s Mounjaro, are effective but expensive, costing over $10,000 annually and available only as injections. In good news for needle-shy patients, Novo Nordisk’s oral peptide demonstrated 15.1% weight loss in a late-stage trial. The shift to oral treatments for obesity could be a game-changer, making it easier for primary care doctors to prescribe and patients to adhere, on top of lowering costs and widening access.
The success of GLP-1 therapies for diabetes and obesity highlights the potential of peptides in healthcare. Innovative peptide therapies, including oral options, are emerging for immune-mediated inflammatory conditions (I&I), promising market growth. Protagonist Therapeutics leads in this field, with further breakthroughs expected, offering hope and improved care for I&I patients.